HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toru Miyoshi Selected Research

omega-Chloroacetophenone (Mace)

1/2022Incremental prognostic value of non-alcoholic fatty liver disease over coronary computed tomography angiography findings in patients with suspected coronary artery disease.
1/2021Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction.
1/2019Prognostic Value and Risk Continuum of Noninvasive Fractional Flow Reserve Derived from Coronary CT Angiography.
3/2011Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toru Miyoshi Research Topics

Disease

16Myocardial Infarction
05/2022 - 10/2004
15Coronary Artery Disease (Coronary Atherosclerosis)
05/2022 - 03/2010
15Heart Failure
03/2022 - 03/2011
15Atherosclerosis
01/2022 - 07/2006
10Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 03/2011
8Inflammation (Inflammations)
06/2022 - 01/2008
8Hypertension (High Blood Pressure)
11/2021 - 01/2010
8Stable Angina
02/2021 - 03/2010
7Acute Coronary Syndrome
01/2022 - 01/2014
7Atrial Fibrillation
11/2021 - 07/2009
7Spasm (Spasms)
03/2016 - 01/2014
6Pathologic Constriction (Stenosis)
12/2022 - 09/2008
6Insulin Resistance
03/2022 - 07/2010
6Hypertriglyceridemia
01/2022 - 08/2011
6Ischemia
01/2022 - 10/2005
6Hypertrophy
05/2019 - 12/2010
6Infarction (Infarctions)
01/2016 - 10/2004
5Type 2 Diabetes Mellitus (MODY)
01/2022 - 07/2014
5Fibrosis (Cirrhosis)
01/2021 - 12/2010
5Body Weight (Weight, Body)
05/2019 - 11/2008
4Diabetes Mellitus
05/2022 - 06/2018
4Chest Pain (Chest Pains)
02/2022 - 02/2016
4Death (Near-Death Experience)
01/2022 - 03/2011
4Hypercholesterolemia
01/2022 - 06/2015
4Thrombosis (Thrombus)
06/2019 - 05/2016
4Chronic Renal Insufficiency
01/2019 - 12/2017
4Hyperlipidemias (Hyperlipidemia)
04/2016 - 08/2011
4Neoplasms (Cancer)
12/2015 - 10/2004
3Acute Kidney Injury (Acute Renal Failure)
02/2021 - 01/2015
3Pulmonary Arterial Hypertension
01/2021 - 04/2017
3Unstable Angina
09/2019 - 01/2014
3Cardiomegaly (Heart Hypertrophy)
05/2019 - 02/2014
3Hypoxia (Hypoxemia)
04/2017 - 06/2009
3Atherosclerotic Plaque (Atheroma)
03/2014 - 03/2010
2Non-alcoholic Fatty Liver Disease
05/2022 - 01/2021
2Myocarditis (Carditis)
02/2022 - 01/2021
2Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2022 - 04/2014
2ST Elevation Myocardial Infarction
06/2021 - 01/2015
2Hyperemia
12/2020 - 10/2017
2Proteinuria
01/2019 - 01/2010
2Essential Hypertension
01/2017 - 07/2011
2Coronary Disease (Coronary Heart Disease)
04/2016 - 08/2011

Drug/Important Bio-Agent (IBA)

12Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
05/2022 - 08/2011
8Eicosapentaenoic AcidIBA
06/2018 - 03/2011
7Phenobarbital (Luminal)FDA Link
12/2022 - 01/2015
6oxidized low density lipoproteinIBA
05/2022 - 11/2006
6LipidsIBA
01/2021 - 08/2011
6LDL CholesterolIBA
12/2020 - 07/2011
6Fatty Acid-Binding ProteinsIBA
10/2017 - 07/2010
6Acetylcholine (Acetylcholine Chloride)FDA Link
03/2016 - 01/2015
5Biomarkers (Surrogate Marker)IBA
06/2022 - 07/2013
5Messenger RNA (mRNA)IBA
02/2022 - 10/2004
5Brain Natriuretic Peptide (Natrecor)FDA Link
01/2022 - 07/2009
5voglibose (Basen)IBA
01/2022 - 07/2014
5Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2017 - 11/2008
5olmesartanIBA
03/2014 - 03/2010
4Sodium-Glucose Transport ProteinsIBA
03/2022 - 01/2019
4omega-Chloroacetophenone (Mace)IBA
01/2022 - 03/2011
4Nicorandil (SG 75)IBA
02/2021 - 06/2017
4LDL Lipoproteins (beta Lipoproteins)IBA
01/2020 - 10/2014
4Angiotensin Receptor AntagonistsIBA
03/2019 - 03/2014
4C-Reactive ProteinIBA
01/2018 - 01/2005
4Ezetimibe (Zetia)FDA Link
06/2015 - 08/2011
4Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
11/2008 - 11/2006
3CalciumIBA
06/2022 - 01/2021
3Sodium-Glucose Transporter 2 InhibitorsIBA
03/2022 - 01/2019
31,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA
01/2022 - 01/2019
3Bisoprolol (Concor)FDA LinkGeneric
11/2021 - 08/2011
3MonocrotalineIBA
01/2021 - 04/2017
3Pharmaceutical PreparationsIBA
01/2020 - 04/2017
3pitavastatin (itavastatin)FDA Link
01/2020 - 01/2018
3Glycoside Hydrolase InhibitorsIBA
01/2019 - 07/2014
3Cystatin CIBA
09/2018 - 07/2013
3Ergonovine (Ergometrine)IBA
03/2016 - 09/2015
3Triglycerides (Triacylglycerol)IBA
10/2014 - 07/2011
3Proteins (Proteins, Gene)FDA Link
12/2010 - 01/2008
3Apolipoproteins E (ApoE)IBA
05/2009 - 01/2008
3ApolipoproteinsIBA
05/2009 - 07/2006
2Malondialdehyde (Propanedial)IBA
05/2022 - 09/2019
2Lipoprotein(a)IBA
05/2022 - 06/2018
2evolocumabIBA
05/2022 - 12/2020
2Glucose (Dextrose)FDA LinkGeneric
03/2022 - 01/2022
2Neprilysin (Neutral Endopeptidase)IBA
01/2022 - 01/2019
2DiureticsIBA
01/2022 - 01/2017
2Angiotensin Receptors (Angiotensin II Receptor)IBA
01/2022 - 01/2019
2sacubitril and valsartan sodium hydrate drug combinationIBA
01/2022 - 01/2019
2CreatinineIBA
02/2021 - 12/2020
2Docosahexaenoic AcidsIBA
01/2021 - 01/2021
2Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
01/2021 - 01/2021
2CollagenIBA
01/2021 - 09/2006
2Interleukin-6 (Interleukin 6)IBA
01/2021 - 05/2019
2Immunoglobulins (Immunoglobulin)IBA
01/2021 - 04/2020
2AlbuminsIBA
12/2020 - 01/2010
2Therapeutic UsesIBA
04/2020 - 01/2019
2Epoprostenol (Prostacyclin)FDA LinkGeneric
11/2019 - 04/2017
2Isoproterenol (Isoprenaline)FDA LinkGeneric
01/2019 - 02/2014

Therapy/Procedure

21Percutaneous Coronary Intervention
05/2022 - 03/2009
18Therapeutics
01/2022 - 06/2005
5Stents
01/2019 - 05/2016
3Catheter Ablation
12/2020 - 09/2008